Many studies have reported significant reduction in alcohol intake and improvements in other addictive behaviors, with ongoing studies looking at its use as a standalone treatment for alcohol and other addictive behaviors
Nollet M, Wisden W, Franks NP
Our MeAgain GLP-1 app logs every dose, injection site, meal, symptom, and progress photo in one place
Molecular Formula : Not applicable (blend) KLOW 5 out of 5 based on 1 customer rating EUR 128.04 EUR 128.04 EUR 128.04 sample KLO is a premium multi-peptide research blend containing TB-500 (10 mg), BPC-157 (10 mg), GHK-Cu (50 mg), and KPV (10 mg) per vial totaling 80 mg of active compounds in lyophilized form
Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
